Nivolumab and Pembrolizumab experience in the second line therapy of your NSCLC patients

Nivolumab and Pembrolizumab experience in the second line therapy of your NSCLC patients

AnnualMeeting2016

3 years
873 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Nathan Pennell, MD of Cleveland Clinic discusses his experience with Nivolumab and Pembrolizumab in the second line therapy of your NSCLC patients
Up Next Autoplay